Astrocytes express ion channels, transmitter receptors, and transporters and, thus, are endowed with the machinery to sense and respond to neuronal activity. Recent studies have implicated that astrocytes play important roles in physiology, but these cells also emerge as crucial actors in epilepsy. Astrocytes are abundantly coupled through gap junctions allowing them to redistribute elevated K⁺ and transmitter concentrations from sites of enhanced neuronal activity. Investigation of specimens from patients with pharmaco-resistant temporal lobe epilepsy and epilepsy models revealed alterations in expression, localization, and function of astroglial K⁺ and water channels. In addition, malfunction of glutamate transporters and the astrocytic glutamate-converting enzyme, glutamine synthetase, has been observed in epileptic tissue. These findings suggest that dysfunctional astrocytes are crucial players in epilepsy and should be considered as promising targets for new therapeutic strategies.

Astrocytes are active partners in neural information processing. Astrocytic processes contact the vasculature or dynamically enwrap thousands of synapses to modulate neuronal activity through the uptake and release of neurotransmitters (Halassa and Haydon 2010; Araque et al. 2014). The intimate morphological and physiological interconnection between both cell types gave rise to the concept of tripartite synapses, which comprises not only pre- and postsynaptic elements but also the astrocytic process. Astrocytes seem to be key players in fundamental brain functions, for example, in learning and memory (Henneberger et al. 2010), in the control of sleep (Halassa et al. 2009), and breathing (Gourine et al. 2010).

Despite the fact that the pathways enabling activation of astrocytes under physiological conditions are still ill determined, a critical role of astrocyte dysfunction in the pathogenesis of neurological disorders is increasingly acknowledged (Seifert et al. 2006). In this review, we will discuss recent work on neurosurgical specimens from patients with pharmaco-resistant mesial temporal lobe epilepsy (MTLE) and corresponding animal models of epilepsy. Our focus will be on expression, subcellular localization, and function of astroglial K⁺ and water channels, gap junctions, glutamate transporters, and the glutamate-converting enzyme, glutamine synthetase (GS), in epileptic tissue.
**K⁺ HOMEOSTASIS IS DISTURBED IN EPILEPSY**

Neuronal activity entails rapid changes of the extracellular K⁺ concentration [K⁺]o (Nicholson and Syková 1998). If increases in [K⁺]o remain uncorrected, the resting potential would become more positive and affect gating of trans-membrane ion channels, receptors, and transporters. During seizure activity in vivo, [K⁺]o may increase up to a ceiling level of 10–12 mM (Heinemann and Lux 1977). Two main mechanisms are thought to balance [K⁺]o during neuronal activity: K⁺ uptake and spatial K⁺ buffering (Kofuji and Newman 2004). K⁺ net uptake through the Na-K-ATPase, or Na-K-Cl cotransporters produces cell swelling and local depolarization of astrocytes. In rodent hippocampus, the Na-K-ATPase has a role in maintaining low [K⁺]o levels and in clearing elevations in [K⁺]o after epileptiform activity (Xiong and Stringer 2000; D’Ambrosio et al. 2002). Whether alterations in net K⁺ uptake contribute to the enhanced [K⁺]o levels seen in epileptic tissue is still unclear. Spatial K⁺ buffering instead is driven by the spatial gradients in membrane potential and K⁺ equilibrium potential within the coupled glial network, which allows transfer of K⁺ from regions of elevated [K⁺]o through the syncytium, to regions of lower [K⁺]o. Spatial buffering depends on distribution and function of astrocytic K⁺ channels, water channels, and gap junctions (Fig. 1) (Kofuji and Newman 2004). It has been reported that the redistribution of K⁺ is preserved in the hippocampal stratum radiatum (but not in the lacunosum-molecular) of mice with coupling deficient astrocytes, indicating that gap-junction-independent mechanisms add to [K⁺]o regulation in the brain (Wallraf et al. 2006).

Because of its presumed role in K⁺ homeostasis, properties of Kir channels in astrocytes have been investigated in experimental and human epilepsy. [K⁺]o assessment with ion-sensitive microelectrodes, and patch-clamp studies suggested that the impaired K⁺ buffering in sclerotic human hippocampus resulted from impaired Kir channel expression. Differences were observed in the effect of Ba²⁺ on stimulus-induced changes in [K⁺]o in brain slices from MTLE patients with (MTLE-hippocampal sclerosis [HS]) or without hippocampal sclerosis (non-HS). In non-HS tissue, Ba²⁺ enhanced [K⁺]o, although this effect was not observed in MTLE-HS specimens. Because Ba²⁺ is a blocker of Kir channels and Kir currents are predominantly expressed by astrocytes (Seifert et al. 2009), this finding suggested impaired function of these channels in sclerotic tissue (Kivi et al. 2000). The hypothesis could be confirmed with patch clamp analyses showing decreased Kir currents in MTLE-HS patients (Bordey and Sontheimer 1998; Hinterkeuser et al. 2000). It was concluded that in MTLE-HS, disturbed K⁺ buffering and enhanced seizure susceptibility result from reduced expression of Kir channels (Fig. 1). Kir.4.1 is the main K⁺ channel subunit of astrocytes in rodent and human hippocampus (Schröder et al. 2000; Olsen and Sontheimer 2008; Seifert et al. 2009), and Western blot (Das et al. 2012), and immunohistochemistry (Heuser et al. 2012) confirmed a significant loss of Kir.4.1 protein in human MTLE-HS. Whether these changes are cause or consequence of the epileptic condition remains to be elucidated.

Down-regulation of Kir.4.1 reduced the ability of astrocytes to remove glutamate and K⁺ from the extracellular space (Djukić et al. 2007; Kucheryavikh et al. 2007). General knockout of Kir.4.1 leads to early postnatal lethality (Kofuji et al. 2000), whereas mice with astrocytic channel deletion display epilepsy (Chever et al. 2010; Haj-Yasein et al. 2011). Traumatic brain injury (TBI) leads to impaired K⁺ homeostasis (D’Ambrosio et al. 1999) and spontaneous partial seizures in the neocortex and hippocampus (D’Ambrosio et al. 2005). Immunohistochemistry postinjury revealed loss of Kir.4.1 in the processes of astrocytes attributable to serum extravasation accompanying TBI (Stewart et al. 2010). Dysfunction of the blood–brain barrier (BBB) is also involved in seizure generation (reviewed by Kovacs et al. 2012). Transient opening of the BBB is sufficient for induction of focal epileptogenesis (Seiffert et al. 2004). BBB lesions are initial events in human MTLE, leading to the extravasation of serum albumin, which is...
taken up by neurons, astrocytes, and microglia (Seiffert et al. 2004; Van Vliet et al. 2007; Braganza et al. 2012). Albumin uptake by astrocytes involves transforming growth factor (TGF)-β receptors, resulting in down-regulation of Kir channels and Kir2.3 channels, impaired gap junction coupling and K⁺ buffering, and hyperexcitability (Friedman et al. 2009; Braganza et al. 2012). No changes in astrocytic Kir currents were found in a kainate model of epilepsy (Takahashi et al. 2010). Recently, down-regulation of Kir4.1 mRNA and protein has been reported in the context of epilepsy and inflammation, possibly mediated by the proinflammatory cytokine interleukin (IL)-1β (Zurolo et al. 2012), whereas another study reported enhanced Kir4.1 expression in a rat pilocarpine model (Nagao et al. 2013). Unfortunately, functional consequences of these changes have not been assessed in the latter two studies.

Linkage analysis in children with seizures, ataxia, sensoneural deafness, mental retardation, and electrolytic imbalance (SeSAME or EAST syndrome) identified KCNJ10 as a candidate gene, which encodes Kir4.1 (Bockenhauer et al. 2009; Scholl et al. 2009). Sequencing of the affected KCNJ10 gene revealed loss-of-function mutations of the channel, and heterologous expression confirmed that the mutations affected Kir4.1 function and produced depolarization.
ALTERATIONS OF AQUaporin-4 IN EPILEPSY

Developmental maturation of aquaporin-4 (AQP4) and Kir4.1 expression occurs within the same postnatal time window. Compared with the rather uniform distribution of Kir4.1, AQP4 displays a pronounced laminar profile, with strong expression in vascular regions (i.e., the hippocampal stratum lacunosum-molecular and stratum-molecular of the dentate gyrus). The time course of AQP4 and Kir4.1 up-regulation parallels the reduction of the extracellular space, emphasizing their impact for K\(^+\) homeostasis (Hsu et al. 2007, 2011; Seifert et al. 2009). Ultrastructural analyses showed spatial overlap of Kir4.1 and the water channel AQP4 in astroglial endfeet (Nielsen et al. 1997; Higashi et al. 2001), and suggested that K\(^+\) clearance through Kir channels might depend on transmembrane flux of water dissipating osmotic imbalances because of K\(^+\) redistribution. In line with this idea, clearance of extracellular K\(^+\) was compromised if the number of perivascular AQP4 channels decreased (Amiry-Moghaddam et al. 2003b), and impaired K\(^+\) buffering and prolonged seizures occurred in AQP4 knockout mice (Binder et al. 2006). However, spatial K\(^+\) redistribution was more efficient in the absence of AQP4, probably because of enhanced astroglial gap-junction coupling and volume regulation (Benfenati et al. 2011; Strohschein et al. 2011), and AQP4-independent Kir4.1 function has been confirmed (Ruiz-Ederra et al. 2007; Zhang and Verkman 2008).

MTLE-HS patients showed loss of AQP4 immunoreactivity in vasculature-associated astrocyte endfeet (Eid et al. 2005). In patients presenting with focal cortical dysplasia and epilepsy (FCD type IIB), higher AQP4 expression was found in the neuropil and around dysplastic neurons while immunoreactivity around blood vessels was also decreased (Medici et al. 2011). This decrease of perivascular AQP4 channels might be secondary, following disruption of the dystrophin complex that is essential for membrane anchoring of AQP4 (Amiry-Moghaddam et al. 2003a; Kim et al. 2010). Recently, a kainate model of MTLE was used to investigate whether the observed loss of perivascular AQP4 is involved in epileptogenesis or merely represents a compensatory effect of the condition. The data show that AQP4 mislocalization precedes the chronic phase of the disorder, indicating its pathophysiological relevance.

Patients with MTLE-HS and antecedent febrile seizures (FS) carry single nucleotide polymorphisms (SNPs) in their AQP4 and KCNJ10 genes. Multivariate analysis identified a correlation between SNPs in these two genes and the incidence of MTLE-HS with FS (Heuser et al. 2010). One of the SNPs in the KCNJ10 gene was associated with seizure resistance (Buono et al. 2004; Lenzen et al. 2005).

Together, these findings suggest that, in MTLE, dislocation of AQP4 channels in concert with decreased expression of Kir channels in astrocytes contribute to impaired K\(^+\) buffering and increased seizure propensity (Fig. 1).

A ROLE FOR ALTERED GAP-jUNCTION COUPLING IN EPILEPSY?

The abundant expression of gap junctions in astrocytes and their formation as a functional network enables long-range intercellular exchange of ions, metabolites, amino acids, and nucleotides. Astrocytic gap junctions are mainly formed by connexin (Cx) 43 and Cx30. Intercellular trafficking of glucose through the astrocytic network and delivery of energetic metabolites from blood vessels to neurons is important to maintain synaptic activity (Rouach et al. 2008), but also to enable spatial redistribu-
tion of K⁺ and glutamate (Wallraff et al. 2006). Accordingly, astrocyte gap-junction coupling in principle may exert pro- as well as antiepileptic effects.

The role of interastrocytic coupling in the development and progression of epilepsy is still elusive. The reason behind this unsatisfactory situation is the fact that, despite various connexin expression studies, virtually no information is available about functional coupling of astrocytes under this condition. With regard to the expression studies, enhanced, decreased, or unaltered expression of connexin 43 and/or Cx30 transcripts and protein has all been reported, both in human epilepsy and in various animal models (reviewed in Giaume et al. 2010; Steinhäuser et al. 2012). However, Cx expression does not necessarily reflect functional coupling because posttranslational modifications may alter unitary conductance, open probability, trafficking, or internalization, making functional coupling analyses indispensable.

Unfortunately, not a single study has yet investigated functional coupling of astrocytes in human epilepsy, whereas findings from animal models are conflicting. In a kainate model and in hippocampal slice cultures chronically exposed to the GABA_A receptor antagonist, bicuculline, increased astrocytic coupling has been reported (Samoilova et al. 2003; Takahashi et al. 2010). In contrast, Xu et al. (2009) observed decreased coupling in the hippocampal CA1 region in a tuberous sclerosis epilepsy model.

Another approach to assess gap-junction coupling in epilepsy is pharmacological inhibition of interastrocytic communication. Such experiments have been performed in a variety of in vivo and in vitro models of epilepsy (Perez-Velazquez et al. 1994; Ross et al. 2000; Kohling et al. 2001; Jahromi et al. 2002; Szente et al. 2002; Gajda et al. 2003; Samoilova et al. 2003, 2008; Bostanci and Bagirici 2006, 2007; Medina-Ceja et al. 2008; Voss et al. 2009). Most of these studies reported anticonvulsive effects of gap-junction blockade although opposite effects were observed by Voss et al. (2009). In neocortical slices from patients with MTLE or focal cortical dysplasia, gap-junction inhibitors attenuated epileptiform activity (Gigout et al. 2006). Major problems with gap-junction blockers are their significant side effects and poor Cx isoform- (and, hence, cell-type-) specificity, which complicate interpretation of these experiments.

In conclusion, Cx expression studies and functional coupling analyses yield an inconsistent picture of the role of the astroglial network in the pathophysiology of epilepsy (Fig. 1). Systematic coupling analysis at different time points during experimental epileptogenesis and in human epileptic specimens is urgently needed to clarify this important question.

GLUTAMATE UPTAKE AND EPILEPSY

Uptake of glutamate is mainly mediated by transporters localized at astrocytic membranes, and altered activity of the astrocytic transporters, EAAT1 and EAAT2, seems to be a common feature of epilepsy and other brain disorders (Seifert et al. 2006). Excess of extracellular glutamate characterizes human epileptic tissue and induces recurrent seizures and neuronal death (Fig. 1) (Glass and Dragunow 1995).

Our picture about the regulation of glial glutamate transporters in human epilepsy is inconsistent. Using in situ hybridization and Western blot in specimens from MTLE-HS patients, Tessler et al. (1999) and Eid et al. (2004) did not find changes of EAAT1 or EAAT2. In contrast, other groups reported down-regulation of EAAT2 in the CA1 region in human HS (Mathern et al. 1999; Proper et al. 2002). Increased EAAT1 levels were noted in the sclerotic CA2/3 region (Mathern et al. 1999), whereas later work showed down-regulation of EAAT1 and EAAT2 in the CA1 region in MTLE-HS (Fig. 1), and emphasized that it remained unclear whether this reduction was causative of the condition or of compensatory nature (Sarac et al. 2009). Epilepsy patients presenting with focal cortical dysplasia (FCD) showed lower EAAT-1 and EAAT-2 immunoreactivity and more diffuse expression patterns as compared with idiopathic epilepsy cases or postmortem controls (Ulu et al. 2010). β-Lactam antibiotics increase glutamate uptake in astrocytes through NF-κB-mediated EAAT2-promoter activation, which might represent a therapeutic tool to
counteract glutamate transporter dysfunction (Lee et al. 2008).

In a model of cortical dysplasia, pharmacological inhibition of glial glutamate transporters in the lesion area provoked opening of neuronal N-methyl-D-aspartate (NMDA) receptors, prolonged synaptic currents, and decreased the threshold for the induction of epileptiform activity (Campbell and Hablitz 2008). Accelerated astrocytic glutamate uptake was observed after kainate-induced status epilepticus (SE) (Takahashi et al. 2010). In the hippocampus of spontaneously epileptic rats, EAAT1 transcripts and protein were decreased, whereas EAAT2 remained unaffected (Guo et al. 2010). Inhibition of glutamate transporters shortened the latency for onset of epileptiform discharges in a low Mg$^{2+}$ slice model, suggesting a role for ambient glutamate in the genesis and maintenance of seizure activity (Nyitrai et al. 2010).

GLUTAMATE DEGRADATION

Once taken up by astrocytes via glutamate transporters (discussed above), glutamate must be sequestered and degraded. This is because glutamate transporters are inherently bidirectional, so intracellular elevations of glutamate concentration within astrocytes will ultimately lead to its electrochemical gradient-mediated release. Failure to degrade glutamate leads to its extracellular accumulation, which has deleterious effects on the function and survival of neurons. In addition, because synaptic terminals are at remote locations from the cell bodies of neurons, this necessitates there to be a local economy at synapses requiring proximate recycling of neurotransmitter for continued function. Once inactivated, neurotransmitter intermediaries must be shuttled back to synapses where an appropriate neurotransmitter can be regenerated through mitochondrial enzymes.

Part of this glutamate degradation process is accomplished through the activity of glutamate dehydrogenase, which catalyzes the formation of α-ketoglutarate from glutamate, providing an intermediary in the tricarboxylic acid (TCA) cycle. This allows its use as a metabolic fuel (Dennis et al. 1977). A second prevalent pathway involves the keystone enzyme in the glutamate degradation process, GS, which is localized predominantly in astrocytes in the brain. GS catalyzes the enzymatic conversion of glutamate to glutamine. Glutamine is then shuttled to neurons via specific glutamine transporters, where it can be reconverted to glutamate by the mitochondrial enzyme, phosphate-activated glutaminase. In addition to its pivotal role in ammonia detoxification, the glutamine–glutamate cycle is critical in the synthesis of neuronal glutamate for use as a neurotransmitter (van den Berg and Garfinkel 1971; Benjamin and Quastel 1975; Tani et al. 2014), and, in interneurons, of subsequent decarboxylation of glutamate to form the inhibitory neurotransmitter, GABA, via the glutamine–glutamate–GABA cycle (Liang et al. 2006; Fricke et al. 2007; Yang and Cox 2011).

GLUTAMINE–GLUTAMATE–GABA CYCLES IN TEMPORAL LOBE EPILEPSY

In patients with temporal lobe epilepsy (TLE), there are abnormally high concentrations of extracellular glutamate, both during and between seizure episodes (i.e., in both ictal and interictal periods) (During and Spencer 1993; Petroff et al. 2004; Cavus et al. 2005). This elevation of extracellular glutamate is much more evident in patients with HS (gliosis) than in patients without sclerosis (Kim et al. 2004; Petroff et al. 2004). Perhaps causally related to this elevated extracellular glutamate concentration in hippocampus of patients with TLE, in tissue resected from these patients there is a significant loss of GS in astrocytes, as well as a significant reduction in GS enzymatic activity (Fig. 1) (Eid et al. 2004; van der Hel et al. 2005). This down-regulation in GS expression and function in hippocampus of epilepsy patients is accompanied by changes in expression and function of astrocytic glutamate transporters, as discussed above.

These static, neuropathological and biochemical findings in patients raise the related questions. Are GS changes (and concomitant disrupted function of the glutamine–glutamate cycle) a cause or a consequence of epilepsy? Do
they contribute to ongoing pathological function, or are they a reflection of excitotoxic damage associated with aberrant activity? These have been addressed, in part, by a series of studies in experimental systems. A first set of experiments centered on the chicken/egg question regarding GS down-regulation in epilepsy, which is, is compromised expression of GS an epiphenomenon, or a causative factor in TLE? To address this, Eid and colleagues continuously infused the GS antagonist, methionine sulfoximine (MSO) into the hippocampus of rats for 28 days, and examined the consequences on epilepsy development (Eid et al. 2008; Wang et al. 2009). They found that animals treated with MSO developed epilepsy and neuropathological features similar to MTLE-HS, supporting a role for GS down-regulation in the pathogenesis of the epileptic condition.

CONSEQUENCES OF GS DOWN-REGULATION ON SYNAPTIC TRANSMISSION AND CIRCUIT EXCITABILITY

In addition to contributing to extracellular glutamate accumulation in the sclerotic hippocampus of TLE patients, a series of recent studies have suggested that GS down-regulation and disruption of the glutamine–glutamate cycle may also have significant effects on hippocampal circuit excitability by differential effects on inhibitory and excitatory synaptic function.

The glutamine–glutamate cycle begins with the uptake of synaptically released glutamate by glutamate transporters in ensheathing astrocytic processes. Glutamate is converted to glutamine via GS inside astrocytes. Glutamine is then shuttled back to presynaptic terminals of neurons through specific glutamate transporters localized in astrocytes and neurons. In nerve terminals, glutamine is reconverted to glutamate through the activity of phosphate-activated glutaminase in mitochondria. Glutamate is available directly as a neurotransmitter for packaging in synaptic vesicles in excitatory terminals, or is converted to GABA by decarboxylation in inhibitory terminals (the glutamine–glutamate–GABA cycle). Release of synaptic glutamate then completes the cycle (reviewed in Chaudry et al. 2002; Bak et al. 2006).

Given the nature of the glutamine–glutamate cycle and the local neurotransmitter economy in synapses, it would be expected that interfering with the cycle at any stage would rapidly impact neurotransmitter supply, and synaptic function. This was found to be the case for hippocampal and thalamic inhibitory synapses, in which application of GS antagonists, gluta
tate uptake blockers, or glutamine transporter blockers all rapidly depleted synaptic release of GABA, which could be reversed by supply of exogenous glutamine (Liang et al. 2006; Fricke et al. 2007; Yang and Cox 2011). Surprisingly, excitatory synaptic transmission is much less sensitive to disruption of the glutamine–glutamate cycle. In studies examining the effects of glutamine–glutamate cycle blockades, little compromise in excitatory synaptic function was evident until protracted periods of synaptic release had occurred (Kam and Nicoll 2007; Tani et al. 2014). This may be because of higher reserve pools of cytoplasmic glutamate being accessible to excitatory neurons, buffering the immediate effects of loss of glutamine–glutamate cycle function. However, the net interpretation of these studies is clear. In situations, in which the glutamine–glutamate cycle is compromised (as occurs with loss of GS expression in epilepsy), the predominant proximate effect may be to reduce GABA release from inhibitory synapses, enhancing circuit excitability.

This line of experimentation has been extended to explore the potential role of astrogliosis in excitability defects underlying seizure predisposition in TLE. Reactive gliosis develops in many neurologic disorders, including, notably, epilepsy and, as was discussed above, is associated with a down-regulation in GS expression. However, the role astroglial reactivity may play in the etiology of epilepsy and other neurologic conditions is poorly understood, in part because of the numerous additional, potentially contributory changes evident following an epileptogenic injury. To isolate the role reactive astrogliosis may play in generating excitability defects in hippocampal circuits, Ortinski et al. (2010) induced reactive astrogliosis using a cell-
specific viral strategy, and then studied the effects of gliosis on circuit excitability.

Virally induced astrogliosis shared many of the hallmarks of reactivity seen in vivo: virally treated astrocytes showed hypertrophy accompanied by increased vimentin and glial fibrillary acidic protein (GFAP) expression, and a down-regulation in GS expression. Notably, neighboring neurons showed no alterations in their anatomy and intrinsic properties. In regions with virally transduced, reactive astrocytes, GABAergic inhibition, but not glutamatergic excitation, was significantly compromised (Fig. 1), and circuit excitability was enhanced in area CA1 of the hippocampus, specifically evident as hyperactivation of direct cortical inputs to the distal dendrites of CA1 neurons (Ortinski et al. 2010). This pathway has been previously shown to be extensively regulated by local circuit inhibition (Empson and Heinemann 1995; Soltesz 1995; Ang et al. 2005), and to be extensively hyperactive in epileptic animals (Denslow et al. 2001; Wozny et al. 2005; Ang et al. 2006). Importantly, all of these astrogliosis-mediated effects could be mimicked by blockers of the glutamine–glutamate cycle and occluded by these same blockers, and were reversed by a supply of exogenous glutamine, supporting a role for gliosis-induced GS down-regulation in the circuit excitability defects underlying epilepsy.

CONCLUDING REMARKS

The pivotal role played by astrocytes in regulating normal brain functions clearly extends to a pathophysiological role in epilepsy. As is discussed above, astrocytes play a number of essential roles in brain function, including regulation of $K^+$ and glutamate homeostasis, as well as in the supply of neurotransmitter precursors for reuse at excitatory and inhibitory synapses. These normal functions are all significantly perturbed in epilepsy. Associated with the development of gliosis in the brains of patients with epilepsy and in animal models of this disorder, there is accumulating evidence for loss of appropriate $K^+$ homeostasis and accompanying changes in aquaporin, gap-junction expression and function, compromised uptake and metabolism of glutamate in astrocytes, and disrupted neurotransmitter supply, particularly in inhibitory neurons. In addition to being potentially linked with gliosis, these biochemical changes have significant functional consequences, contributing to the circuit hyperexcitability that is the hallmark of epilepsy. This further implicates compromised astrocyte dysfunction in the pathophysiology of epilepsy. In addition to providing new information about causal factors in epilepsy development and expression, this role of astrocytes suggests new avenues for therapeutic interventions with significant promise.

ACKNOWLEDGMENTS

Research of the authors is supported by the National Institutes of Health (P01 NS054900 and P20 MH71705), the Deutsche Forschungsgemeinschaft (STE 552/3, STE 552/4), and the EU (EuroEPINOMICS). We thank Dr. I. Heuer for help with graphical work and apologize to all colleagues whose findings could not be discussed because of space constraints.

REFERENCES


Cite this article as Cold Spring Harbor Perspectives in Medicine 2015;5:a022434

Astrocytes in Epilepsy
Astrocytes in Epilepsy


### Role of Astrocytes in Epilepsy

Douglas A. Coulter and Christian Steinhäuser

*Cold Spring Harb Perspect Med* 2015; doi: 10.1101/cshperspect.a022434

#### Subject Collection

<table>
<thead>
<tr>
<th>Topic</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Epilepsy Spectrum: Targeting Future Research Challenges</strong></td>
<td>Gregory L. Holmes and Jeffrey L. Noebels</td>
</tr>
<tr>
<td><strong>Role of Sodium Channels in Epilepsy</strong></td>
<td>David I. Kaplan, Lori L. Isom and Steven Petrou</td>
</tr>
<tr>
<td><strong>Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet</strong></td>
<td>Michael A. Rogawski, Wolfgang Löscher and Jong M. Rho</td>
</tr>
<tr>
<td><strong>Epilepsy and Autism</strong></td>
<td>Ashura W. Buckley and Gregory L. Holmes</td>
</tr>
<tr>
<td><strong>Immunity and Inflammation in Epilepsy</strong></td>
<td>Annamaria Vezzani, Bethan Lang and Eleonora Aronica</td>
</tr>
<tr>
<td><strong>Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channels in Epilepsy</strong></td>
<td>Gary P. Brennan, Tallie Z. Baram and Nicholas P. Pooles</td>
</tr>
<tr>
<td><strong>The Role of Calcium Channels in Epilepsy</strong></td>
<td>Sanjeev Rajakulendran and Michael G. Hanna</td>
</tr>
<tr>
<td><strong>Interneuron Transplantation as a Treatment for Epilepsy</strong></td>
<td>Robert F. Hunt and Scott C. Baraban</td>
</tr>
<tr>
<td><strong>Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy</strong></td>
<td>Andrey Mazarati and Raman Sankar</td>
</tr>
<tr>
<td><strong>The Diathesis–Epilepsy Model: How Past Events Impact the Development of Epilepsy and Comorbidities</strong></td>
<td>Christophe Bernard</td>
</tr>
<tr>
<td><strong>Potassium Channels in Epilepsy</strong></td>
<td>Rüdiger Köhling and Jakob Wolfart</td>
</tr>
<tr>
<td><strong>GABAergic Synchronization in Epilepsy</strong></td>
<td>Roustem Khazipov</td>
</tr>
<tr>
<td><strong>Status Epilepticus</strong></td>
<td>Syndi Seinfeld, Howard P. Goodkin and Shlomo Shinnar</td>
</tr>
<tr>
<td><strong>Neonatal and Infantile Epilepsy: Acquired and Genetic Models</strong></td>
<td>Aristea S. Galanopoulou and Solomon L. Moshé</td>
</tr>
<tr>
<td><strong>Epigenetics and Epilepsy</strong></td>
<td>David C. Henshall and Katja Kobow</td>
</tr>
<tr>
<td><strong>Microcircuits in Epilepsy: Heterogeneity and Hub Cells in Network Synchronization</strong></td>
<td>Anh Bui, Hannah K. Kim, Mattia Maroso, et al.</td>
</tr>
</tbody>
</table>

For additional articles in this collection, see [http://perspectivesinmedicine.cshlp.org/cgi/collection/](http://perspectivesinmedicine.cshlp.org/cgi/collection/)

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved